|
|
|
|
|
|
|
|
Markman: onclive
Early promising responses seen with immune checkpoint inhibitors for patients with ovarian cancer still need to be validated in larger randomized trials before a conclusion is made regarding their true efficacy, according to a presentation by Maurie Markman, MD, at the 33rd Annual Chemotherapy Foundation Symposium.
“The checkpoint inhibitors are not ready for prime time yet in ovarian cancer. It's not because there's evidence that they don't work—it's just that there's no evidence at all,” said Markman, president of Medicine and Science at the Cancer Treatment Centers of America. “You could not think of a more appropriate tumor type to explore the concept of immunotherapy than ovarian cancer. Unfortunately, as we've all learned, it's much more complicated.”....
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.